← Back to Screener
Autolus Therapeutics plc American Depositary Share (AUTL)
Price$1.58
Favorite Metrics
Price vs S&P 500 (26W)-11.13%
Price vs S&P 500 (4W)4.72%
Market Capitalization$425.83M
All Metrics
Book Value / Share (Quarterly)$1.30
P/TBV (Annual)3.31x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)128.01%
Price vs S&P 500 (YTD)-24.53%
Gross Margin (TTM)-27.83%
Net Profit Margin (TTM)-381.40%
EPS (TTM)$-1.08
10-Day Avg Trading Volume1.46M
EPS Excl Extra (TTM)$-1.08
Revenue Growth (5Y)112.99%
EPS (Annual)$-1.08
ROI (Annual)-64.13%
Gross Margin (Annual)-26.10%
Net Profit Margin (5Y Avg)-4654.61%
Cash / Share (Quarterly)$1.71
Revenue Growth QoQ (YoY)83655.17%
ROA (Last FY)-48.81%
Revenue Growth TTM (YoY)644.94%
EBITD / Share (TTM)$-0.98
ROE (5Y Avg)-99.04%
Operating Margin (TTM)-358.87%
Cash Flow / Share (Annual)$-0.30
P/B Ratio2.39x
P/B Ratio (Quarterly)2.94x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)7.85x
Net Interest Coverage (TTM)-17.39x
ROA (TTM)-42.31%
EPS Incl Extra (Annual)$-1.08
Current Ratio (Annual)5.94x
Quick Ratio (Quarterly)5.19x
3-Month Avg Trading Volume1.97M
52-Week Price Return10.49%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$1.25
P/S Ratio (Annual)5.65x
Asset Turnover (Annual)0.13x
52-Week High$2.70
Operating Margin (5Y Avg)-4610.29%
EPS Excl Extra (Annual)$-1.08
CapEx CAGR (5Y)13.07%
Tangible BV CAGR (5Y)-9.06%
26-Week Price Return-4.24%
Quick Ratio (Annual)5.19x
13-Week Price Return9.72%
Total Debt / Equity (Annual)1.52x
Current Ratio (Quarterly)5.94x
Enterprise Value$591.894
Revenue / Share Growth (5Y)53.36%
Asset Turnover (TTM)0.11x
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-378.78%
Cash / Share (Annual)$3.53
3-Month Return Std Dev62.88%
Net Income / Employee (TTM)$-0
ROE (Last FY)-161.42%
Net Interest Coverage (Annual)-7.18x
EPS Basic Excl Extra (Annual)$-1.08
Receivables Turnover (TTM)5.49x
Total Debt / Equity (Quarterly)1.52x
EPS Incl Extra (TTM)$-1.08
Receivables Turnover (Annual)5.49x
ROI (TTM)-52.38%
P/S Ratio (TTM)5.65x
Pretax Margin (5Y Avg)-4933.00%
Revenue / Share (Annual)$0.28
Price vs S&P 500 (52W)-24.14%
Year-to-Date Return-20.60%
5-Day Price Return6.76%
EPS Normalized (Annual)$-1.08
ROA (5Y Avg)-39.58%
Net Profit Margin (Annual)-381.40%
Month-to-Date Return14.49%
Cash Flow / Share (TTM)$-0.97
EBITD / Share (Annual)$-0.98
Operating Margin (Annual)-358.87%
LT Debt / Equity (Annual)1.52x
ROI (5Y Avg)-53.19%
LT Debt / Equity (Quarterly)1.52x
EPS Basic Excl Extra (TTM)$-1.08
P/TBV (Quarterly)3.31x
P/B Ratio (Annual)2.94x
Inventory Turnover (TTM)5.16x
Pretax Margin (TTM)-378.78%
Price vs S&P 500 (13W)7.34%
Beta2.09x
Revenue / Share (TTM)$0.28
ROE (TTM)-99.05%
52-Week Low$1.15
Industry Peers — Biological Products(88)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
AUTLAutolus Therapeutics plc American Depositary Share | 5.65x | 644.94% | -27.83% | — | $1.58 |
AMGNAmgen Inc | 5.20x | 9.95% | 73.30% | 2.93% | $350.16 |
GILDGilead Sciences Inc | 5.71x | 2.40% | 78.83% | 133.64% | $135.87 |
ARGXargenx SE American Depositary Shares | 12.59x | 89.56% | 150.91% | — | $834.45 |
BNTXBioNTech SE American Depositary Share | 9.06x | -11.81% | 84.21% | — | $105.19 |
BIIBBiogen Inc. Common Stock | 2.72x | 2.22% | 75.69% | -18.77% | $183.34 |
MRNAModerna, Inc. Common Stock | 10.91x | -39.93% | 70.32% | — | $54.59 |
NBIXNeurocrine Biosciences Inc | 4.64x | 21.45% | 98.18% | 2.31% | $131.59 |
EXELExelixis Inc | 4.89x | 6.85% | 96.39% | 31.10% | $43.61 |
TECHBio-Techne Corp. | 7.72x | 1.64% | 66.60% | -20.58% | $60.58 |
IBRXImmunityBio, Inc. Common Stock | 74.42x | 668.31% | 99.34% | — | $8.20 |
About
Autolus Therapeutics develops next-generation programmed T-cell therapies for cancer treatment. The biopharmaceutical company's clinical-stage pipeline is anchored by Obe-cel and includes several additional programs (AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7, and AUTO8) at varying developmental stages.